No Data
Jefferies Initiates Silence Therapeutics(SLN.US) With Buy Rating, Announces Target Price $40
Jefferies analyst Kelly Shi initiates coverage on $Silence Therapeutics(SLN.US)$ with a buy rating, and sets the target price at $40.According to TipRanks data, the analyst has a success rate of 42.3%
HC Wainwright & Co. Reiterates Buy on Silence Therapeutics, Maintains $75 Price Target
Silence Therapeutics Analyst Ratings
H.C. Wainwright Maintains Silence Therapeutics(SLN.US) With Buy Rating, Maintains Target Price $75
H.C. Wainwright analyst Patrick Trucchio maintains $Silence Therapeutics(SLN.US)$ with a buy rating, and maintains the target price at $75.According to TipRanks data, the analyst has a success rate
Silence Therapeutics: Strong Buy on Underappreciated Blockbuster Potential and Clinical Advancements
Silence Therapeutics to Webcast Presentations at Upcoming September Investor Conferences